Sektory a témata
Healthcare and Biotech in a Portfolio: Stability and Speculation
Key takeaways
- Healthcare is a defensive sector with a low beta to the economic cycle.
- The biotech segment adds a strong speculative component — companies move on clinical trial results.
- UCITS ETFs cover the entire sector or allow separation of healthcare vs. pure biotech.
- Regulatory risk (drug approvals, price regulation) is a key factor for the sector.
- Aging demographic trends structurally drive long-term demand upward.
Healthcare is one of the few sectors where defensive stability and high-risk speculation coexist side by side — in a single sector ETF you will find pharmaceutical giants with decades of history alongside biotech companies dependent on a single clinical trial.
Sector structure
Healthcare is typically divided into four segments: pharmaceuticals (large companies with diversified pipelines), medical devices and diagnostics, healthcare providers and insurers, and biotech. Each segment has a completely different risk and return profile. A broader "healthcare" ETF mixes defensive pharma with significantly more speculative biotech.
UCITS ETFs for healthcare
UCITS funds tracking global healthcare indices or specifically biotech are available on the European market. When selecting, consider:
- Breadth vs. focus — a global healthcare ETF is more conservative than a pure biotech fund.
- Geographic split — the US dominates, but Japan and Europe have strong pharmaceutical companies.
- Drug patent and pipeline exposure — patent expiry on a key drug can knock a stock down by a third.
Risks that catch people off guard
The biggest risks are regulatory — FDA approvals, the European CHMP, drug price regulation (especially politically sensitive in the US). Biotech companies can lose 50–80% of their value when a clinical trial fails. Pharmaceutical giants face patent expirations and generic competition. Read how to measure risk in investments in general.
Place in the portfolio
A broader healthcare ETF can form a conservative satellite position of 5–10% as a complement to a core global index. Pure biotech is speculation suitable only for a small portion of the portfolio. The fundamentals of portfolio construction are covered in the first portfolio guide.
FAQ
Why is healthcare a defensive sector?
Demand for medicines and healthcare is relatively independent of the economic cycle — people get treatment even in recessions. Therefore, healthcare ETFs tend to be less volatile than technology or cyclical sectors.
What is the difference between a healthcare ETF and a biotech ETF?
A healthcare ETF covers the entire sector — from insurers to pharmaceuticals. A biotech ETF is narrower and riskier: companies depend on clinical trials and can lose a significant portion of their value upon failure.
How can I invest in biotech safely?
There is no safe path into biotech. The safest approach is diversification through an ETF rather than selecting individual stocks, and a strict limit to a small portion of the portfolio — a maximum of 3–5%.